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Poor clinical outcomes in cancer can often be attributed to inadequate response to chemotherapy. Strategies to overcome either
primary or acquired chemoresistance may ultimately impact on patients’ survival favourably. We previously showed that lower levels
of SPARC were associated with therapy-refractory colorectal cancers (CRC), and that upregulating its expression enhances chemo-
sensitivity resulting in greater tumour regression in vivo. Here, we examined aberrant hypermethylation of the SPARC promoter as a
potential mechanism for repressing SPARC in CRCs and whether restoration of its expression with a demethylating agent 5-Aza-
20deoxycytidine (5-Aza) could enhance chemosensitivity. Initially, the methylation status of the SPARC promoter from primary human
CRCs were assessed following isolation of genomic DNA from laser capture microdissected specimens by direct DNA sequencing.
MIP101, RKO, HCT 116, and HT-29 CRC cell lines were also used to evaluate the effect of 5-Aza on: SPARC promoter methylation,
SPARC expression, the interaction between DNMT1 and the SPARC promoter (ChIP assay), cell viability, apoptosis, and cell
proliferation. Our results revealed global hypermethylation of the SPARC promoter in CRCs, and identified specific CpG sites that
were consistently methylated in CRCs but not in normal colon. We also demonstrate that SPARC repression in CRC cell lines could
be reversed following exposure to 5-Aza, which resulted in increased SPARC expression, leading to a significant reduction in cell
viability (by an additional 39% in RKO cells) and greater apoptosis (an additional 18% in RKO cells), when combined with 5-FU in vitro
(in comparison to 5-FU alone). Our exciting findings suggest potential diagnostic markers of CRCs based on specific methylated CpG
sites. Moreover, the results reveal the therapeutic utility of employing demethylating agents to improve response through
augmentation of SPARC expression.
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The molecular pathogenesis associated with colorectal cancer
(CRC), as the second leading cause of cancer death in North
America, is the focus of extensive investigation. Many of the
genetic changes leading to the multi-step progression from
adenoma to carcinoma have been described, such as mutations
of the adenomatous polyposis coli (APC) gene, K-Ras (Morris et al,
1996), SMAD2, SMAD4 (Thiagalingam et al, 1996), p53 (Nigro
et al, 1989), and mismatch repair genes (hMSH2, hMLH1, PMS1,
GTBP (Kinzler and Vogelstein, 1996; Perucho, 1996; Chung, 2000).
Hypermethylation of various genes have also been implicated in
colorectal cancer development and progression (Toyota et al,
1999). Examples include several tumour suppressor genes, such as
INK4A(p16) cell cycle regulator (Herman et al, 1995), as well as
others, such as hMLH1 nucleoside mismatch repair gene (Kane
et al, 1997), THBS1 angiogenesis inhibitor (Ahuja et al, 1997), and
TIMP3 metastasis suppressor (Cameron et al, 1999).
Secreted protein acidic and rich in cysteine (SPARC), also
known as osteonectin, is a matricellular protein involved in wound
repair, cell migration and differentiation (Sage et al, 1989; Yan and
Sage, 1999; Bradshaw and Sage, 2001; Brekken and Sage, 2001). The
expression of SPARC is variable in different cancers, and its role in
tumorigenesis appears complex and not well defined (Wewer et al,
1988; Bellahcene and Castronovo, 1995; Ledda et al, 1997; Said and
Motamed, 2005; Tai et al, 2005; DiMartino et al, 2006; Rodriguez-
Jimenez et al, 2007). For example, in neuroblastoma SPARC
impairs tumour growth (Chlenski et al, 2006), while in another
type of brain cancer, glioblastoma, SPARC induces metastasis and
invasion (Rich et al, 2003). In some tissues, it appears to have
tumour suppressing properties by conferring growth inhibition to
cancers of the ovaries (Yiu et al, 2001), lung (Brekken et al, 2003),
breast (Dhanesuan et al, 2002), neuroblastomas (Chlenski et al,
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s2002), and leukaemia (DiMartino et al, 2006). In addition, absence
of SPARC in SPARC  /  mice promotes the growth of pancreatic
and lung cancers (Brekken et al, 2003; Puolakkainen et al, 2004),
thereby demonstrating that SPARC is capable of suppressing
tumour growth in certain cancers due to endogenous expression
of, or as a result of exogenous exposure to SPARC. Our laboratory
recently correlated low levels of SPARC expression in colorectal
cancers with decreased sensitivity to chemotherapy, and showed
that reversal of therapy resistance could be achieved by
upregulating SPARC expression or exogenous exposure to higher
levels of SPARC either in vitro or in vivo (Tai et al, 2005). This
change in SPARC expression in tumorigenesis and its role in
promoting chemotherapy sensitivity led us to investigate the
potential mechanisms involved in repressing SPARC in colorectal
cancers. Since aberrant methylation appears to play a role in CRC,
and SPARC promoter hypermethylation appears to be responsible
for its low expression in cancers of the pancreas (Sato et al, 2003),
lung (Suzuki et al, 2005), and leukaemia (DiMartino et al, 2006),
we decided to evaluate the possibility that: (1) this mechanism may
also be involved in suppressing SPARC in CRCs; and (2) whether a
demethylating agent could reverse the methylated state of the
SPARC promoter in CRC, resulting in higher SPARC expression
and greater sensitivity of tumours to chemotherapy.
MATERIALS AND METHODS
Clinical samples, cell lines and DNA extraction
Archival paraffin-embedded tissues of CRC and normal colon were
used to determine the methylation status of the SPARC promoter
(Table 1). All specimens of normal colon were identified from
individuals who had undergone surgery for diverticular disease of
the colon. This study was conducted with permission from our
Institutional Ethics Review Board. From each specimen, genomic
DNA was extracted from the colonic epithelia that were identified
and captured by laser capture microdissection (Figure 1A)
(Molecular Machine & Industries, mCut Laser Microdissection).
Human colorectal cancer cell lines, MIP 101 (Tai et al, 2005),
RKO, HCT116 and HT29 (ATCC), and a normal colon cell line
CCD-112CoN (ATCC), were maintained in DMEM supplemented
with 10% fetal bovine serum; 1% Kanamycin, Streptomycin-
Penicillin, and incubated at 371C and 5% CO2. To determine the
effect of 5-Aza-20deoxycytidine (5-Aza, demethylating agent) on
SPARC promoter methylation, 4mM of 5-Aza was added to the
culture media (Suzuki et al, 2005) for a period of 7 days with media
changes on day 4, before assessing its effect on cell viability (WST-1),
apoptosis (Caspase 3/7 and TUNEL), cell proliferation, and SPARC
promoter methylation (by bisulfite sequencing).
For DNA extraction, microdissected clinical specimens or cells
harvested from CRC cell lines were digested overnight at 421C
(digestion buffer: 10mM Tris-HCl [pH8], 1mM EDTA, 1% Tween
20, 0.5% Proteinase K) then heated to 951C for 10min. One volume
of phenol/chloroform/isoamyl alcohol (25:24:1) was mixed by
inversion with the digested samples and added to the Phase Lock
Gelt Eppendorf tubes. After spinning at 14000 g for 5min at
room temperature, the aqueous layer was removed to which 1mlo f
glycogen (20mg/ml) was added. Precipitation of the DNA was
performed with three volumes of 95% ethanol, 0.1M NaOAc for 2h
at  201C and then centrifuged at 14000 g for 10min at room
temperature. DNA pellets were washed with 70% ethanol, spun at
14000 g for 10min, air dried and resuspended in 10mlo f
modified TE (10mM Tris (pH 8)/0.1mM EDTA).
DNA bisulfite sequencing, methylation-specific PCR, and
RT-PCR
Direct DNA sequencing was performed after bisulfite treatment
(Herman et al, 1996), using Methylamp One-step modification kit
(Epigentek) following the manufacturer’s instructions, with
primers covering a CpG region 1500bp upstream and including
exon1 of SPARC (Figure 1B and C).
Methylation-specific PCR (MSP) was also performed after
bisulfite modification, using methylation-specific primers, which
were designed to recognise bisulfite-induced modifications of
unmethylated cytosines. Two primer sets, MSP1 and MSP2, were
used to target the CpG island located in the putative promoter
region of SPARC (Sato et al, 2003; Wang et al, 2005). Primers
targeting INK4A(p16), a gene found to be hypermethylated in
CRC, were used as control (Mund et al, 2005).
For RT-PCR, mRNA isolated from CRC cell lines were extracted
using Trizol (Invitrogen, Burlington, Ontario, Canada). Primers
used to amplify SPARC and PCR conditions were previously
described (Tai et al, 2005). Amplicons were separated in 2.5%
agarose gel electrophoresis.
Chromatin immunoprecipitation assay
To evaluate the effect of 5-Aza exposure on the interaction between
Dnmt1 (a DNA methyltransferase) with the promoter region of
SPARC, a chromatin immunoprecipitation (ChIP) assay was
performed using a ChIP kit (Epigentek) as per the manufacturer’s
instructions. Cells were fixed with formaldehyde for protein/DNA
crosslinking and lysed. The DNA was sheared by sonication (10
pulses, 30sec on 30sec off) and added to a well coated with the
antibody to the protein of interest (anti-Dnmt1, cat no. A-1001,
Epigentek). Washes were performed to remove unbound material,
while Dnmt1-bound DNA was released by protein digestion with
proteinase K. The DNA was purified through a column and PCR
was performed using primers designed to target the SPARC
promoter region spanning the site of interaction with Dnmt1 (Rhee
et al, 2000), sense 50-CCCCGGAACAGATGAGGCA-30, anti-sense
50-AGGGGAGCCGTGATGGAGCC-30 (annealing 581C), while IN-
K4A(p16) was used as control (Lin et al, 2007). The sole
modification to the manufacturer’s protocol was the blocking of
the antibody-coated well with 1% skim milk for 1h to reduce
background.
Cell viability, proliferation and clonogenic assay
Cell viability was evaluated using WST-1 (Roche) following the
manufacturer’s instructions. Cells were seeded at 50% confluence
per well in triplicate into a 96-well plate and exposed 24h later to
4mM 5-Aza for a total of 5 days, with the addition of 1000mM of
5-FU in the last 24h prior to WST assay. To evaluate the specificity
of the effects of 5-Aza on SPARC promoter methylation, we also
assessed the effect of knocking-down SPARC expression using
SPARC siRNA. Cells seeded in triplicate wells in 96-well plates
were transiently transfected 24h later with SPARC siRNA designed
to target sequences 50-AATTCGAGAAGAACTATAACA-30 and 50-
AATGTGCAAGCTGGATGAGAA-30 (Qiagen, Missassauga, Ontario,
Canada). HiPerfect Reagent (Qiagen) was used for the transient
transfection. Scramble oligonucletide sequences were used as non-
silencing controls for these studies. In all 4mM 5-Aza was added
Table 1 Demographics of patients with colorectal cancer or normal
colon (clinical specimens used in this study)
AJCC staging
(colorectal cancer)
Subject age range
(mean)
Gender
(M/F)
I 44–81 (64) 2/1
II 66–76 (71) 3/1
III 75 (75) 1/0
IV 55–58 (56.5) 2/0
Normal colon 34–68 (54.2) 3/2
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sinto the wells the same day as the siRNA transfection and
incubated for a total of 5 days. Again, cells were also exposed to
1000mM 5-FU in the last 24h prior to WST assay. Three
independent replicates were analyzed, with results represented as
mean±s.e.
To determine the rate of cell proliferation, cells exposed to 5-Aza
for 7 days (and untreated controls) were seeded at 20000 cells
per well into a 48-well plate. Cells were counted from duplicate
wells at 24, 48 and 72h. The effect of a 24-h 5-FU exposure on
cell proliferation, in the presence or absence of 5-Aza, was
also determined. Results were based on two independent
experiments.
For the clonogenic assay, 5-Aza treated and untreated control
cells were seeded at 1000 cells per well in a 48-well plate. Twenty-
four hours later, cells were incubated with 100–1000mM 5-FU for 7
days, with a change in media and drug on day 4. Cells were then
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MSP1
Primers Sense(5′–3′) Antisense(5′-3′)
P1 tgttgtggtatgtgYgtttgtt cactcactctatcRcccaaa
P2 tagggttgggaYgtttggtt tccctcctcctcctatctcc
P3 taYggggtggaggggagagata aaacaaaacRcRctctccRaacaaa
P4 gattgttYggagagYgYgttttg tccctcccttacacacRaactaa
P5 gtttYtgtgtaagggagggaag caaacaaacaaaaccRaaaacc
Figure 1 Histological images of specimens of normal colon or colon cancer before (A-i, iv) and after (A-ii, iii, v, vi) laser capture microdissection (LCM);
only colonic epithelium represented by images (iii) or (vi) were used for analysis. (B) Map of the CpG island in the promoter region at 50 of the SPARC gene,
including regions flanked by the bisulfite sequencing primers (P1–P5, arrows and sequences), numbered CG positions within the sequencing region (grey),
exon1 (boxed). Brackets show regions amplified using methylation-specific primers MSP1 and MSP2. (C) Five sets of primers were used to sequence the
regions shown in (B).
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sstained with 0.2% crystal violet. The number of colonies in the
treated group was calculated based on the colonies formed from
the control, untreated cells. Assays were performed in triplicate.
Apoptosis
Cells that were exposed to 4mM 5-Aza (and untreated controls)
were seeded into a 48-well plate at 100000 cells per well. Twelve
hours later, cells were incubated with 1000mM of 5-FU for an
additional 24h before harvesting the cells for TUNEL assays. To
assess the effect of 5-Aza in the absence of SPARC expression, we
also transiently transfected cells with SPARC siRNA 24-h after
seeding (as described earlier), in combination with 4mM 5-Aza for
a total of 5 days. In the last 24h of incubation with 5-Aza, cells
were also exposed to 1000mM 5-FU prior to harvesting, and
subsequently used for caspase 3/7 assays. Specifically, 20mg of total
protein was isolated from cell lysates, and using a 1:1 dilution of
Caspase Glo-3/7 Substrate (Promega, Madison, WI, USA), relative
luminescence units (RLU) were quantified using Viktor 1420
Multilabel counter (Perkin Elmer), as previously described
(Taghizadeh et al, 2007; Tang and Tai, 2007). For TUNEL assay,
suspension and attached cells were collected and fixed onto glass
slides with Shandon cytospin at 2000r.p.m. for 10min, and
stained using the DeadEnd II Fluorometric TUNEL System
(Promega). The number of TUNEL-positive cells was counted
and averaged from four different fields, with slides read
independently by different individuals in a blinded fashion.
Triplicate assays were performed.
Immunoblotting
Cell lysates from MIP 101 cells incubated with 4mM of 5-Aza for 7
days were collected and processed as previously described (Tai
et al, 2005; Taghizadeh et al, 2007; Tang and Tai, 2007). Antibodies
to SPARC (1mg/ml; Haematologic Technologies Inc.) and tubulin
(0.2mg/ml; Sigma-Aldrich) were used.
Statistics
Statistical difference between experimental groups were analyzed
using Student’s t-test, with significance defined as Po0.05, by
Smith’s Statistical package.
RESULTS
Hypermethylation of the SPARC promoter was more
commonly observed in human colorectal cancers than in
normal colon
To determine more definitively the methylation status of the CpG
sites within the 1500bp region upstream of the SPARC promoter
and including exon 1, bisulfite-treated DNA from microdissected
clinical specimens were sequenced (Herman et al, 1996). Overall, a
significantly higher proportion of CpG sites were methylated
within the SPARC promoter in colorectal cancers (60%), while only
35% of the sites were methylated in normal colon (P¼0.03)
(Figure 2A). The proportion of partially methylated sites were
significantly lower in the colorectal cancers (28%) compared to the
normal colon (46%) (P¼0.04). In the normal colon, there
appeared to be a similar frequency of CpG sites that were either
completely methylated, partially or completely unmethylated. We
also noted that CpG positions 1–2, 8–10, 16–18 were more
frequently methylated in colorectal cancer, in comparison to
normal colon (Figure 2B).
In addition, when we examined the number of colorectal cancers
with greater than 50% methylated CpG sites in the 1500bp region
sequenced, 80% of colorectal cancer (8 of 10 samples) met this
criteria, while only 20% of normal colons (one of five samples)
could be considered as hypermethylated. An interesting observa-
tion was the difference in overall survival between the two patients
with Stage IV colorectal cancer: one patient with hypermethylation
in 95% of the CpG sites examined survived 18 months, while the
other one with hypermethylation in only 60% of the sites survived
37 months. The same patient with Stage IV disease and
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Figure 2 Direct bisulfite DNA sequencing of human colorectal cancers and normal colon in the 1500bp region 50 of the SPARC gene (including exon1-
intron1) (A) The frequency of M¼methylation, P¼partial methylation, and U¼unmethylation at each CpG site (numbers correspond to grey boxes in
Figure 1) is provided for colorectal cancers (tumour) and normal colon (normal). The pattern of methylation considers only the frequency of methylation
within CpG sites with variable status (thus excluding the consistently methylated CpG sites in CRC and controls). (B) Percentage of methylated CpG sites in
the SPARC promotor region in CRC or normal colon samples when considering positions 1–2, 8–10, 16–18 only. Significance was determined Po0.05.
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shypermethylation in 95% of CpG sites within the SPARC promoter
from samples isolated from the tumour also had an area of the
surrounding normal colon examined, and this showed hyper-
methylation in only 50% of the CpG sites. Given the differential
degree of methylation of the SPARC promoter between the tumour
and normal colon within the same individual, this suggests that the
degree of hypermethylation in the SPARC promoter within the
tumour is likely related to the diseased state.
Hypermethylation of the promoter region of SPARC was
observed in colorectal cancer cell lines
We assessed the methylation status of four colorectal cancer cell
lines (MIP101, RKO, HT29, and HCT 116) and one normal colon
cell line (CCD 112CoN) and observed hypermethylation in the
promoter region of MIP 101 and RKO cells flanked by both MSP1
and MSP2 (Figure 3A). In HCT116 and HT29 cells, partial
methylation was noted in both cell lines with methylated CpG
sites in the MSP1 region but unmethylated in the MSP2 region
(Figure 3A). Normal colon cell line CCD-112CoN also showed
partial methylation, with a methylated MSP1 region and un-
methylated MSP2 region (Figure 3A). In addition, we also assessed
the methylation status of the promoter of the INK4A(p16) gene,
which is hypermethylated in colorectal cancer, and noted
hypermethylation in MIP101 and HCT 116 cells, and partial
methylation in RKO and HT 29 CRC cells. Partial methylation was
also observed in the promoter region of this gene in normal colon
cell line CCD-112CoN.
Exposure to a demethylating agent, 5-Aza (4mM), for 7 days in
vitro resulted in a change in the methylation status in the MSP1
and MSP2 regions of the promoters for both SPARC and
INK4A(p16) in all four CRC cell lines (Figure 3B). Unmethylated
regions were now detected after incubation with 5-Aza, especially
in those cell lines (MIP 101 and RKO cells) where there was
complete methylation in both MSP regions. Exposure of HT29 cells
to 5-Aza changed the SPARC promoter from a hemimethylated to a
completely unmethylated state, while there appeared to be no
significant effect of this demethylating agent on HCT 116 cells,
which remained hemimethylated. Reversal of hypermethylation
within the region of the SPARC promoter by 5-Aza was confirmed
by ChIP assays. In all CRC cell lines, an interaction between the
SPARC promoter with Dnmt1 (a DNA methyltransferase that
catalyses the transfer of a methyl group to DNA, resulting in DNA
methylation) could be detected (Figure 3C). However, following
exposure to 5-Aza, this interaction was no longer observed.
Exposure to demethylating agent, 5-Aza-20deoxycytidine,
increases the sensitivity to chemotherapy in colorectal
cancer cells with methylated SPARC promoter
We previously demonstrated that higher levels of SPARC
expression was associated with greater sensitivity to chemotherapy
(Tai et al, 2005). As noted above, hypermethylation of the SPARC
promoter could be reversed following incubation with 5-Aza
(Figure 3B), which also resulted in higher levels of SPARC gene
(Figure 4A and B) and protein (Figure 4C) expression. Therefore,
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Figure 3 Methylation-specific PCR (MSP) and ChIP assays of CRC cells. Primers targeting the promoter-exon 1 region of SPARC were used to determine
its methylation status in: (A) CRC cell lines (MIP101, RKO, HCT116, HT29) and normal colon (CCD-112CoN); and (B) CRC cell lines after exposure to
5-Aza for 7 days. Hypermethylation (MIP101, RKO) as well as hemimethylation (HCT116, HT29) of the promoter region of SPARC was observed, which
resulted in unmethylation of the SPARC promoter after exposure to 5-Aza. (C) ChIP assay showing amplified PCR products of the regions within the SPARC
and INK4A(p16) promoters that interact with Dnmt1 in CRC cell lines not exposed to 5-Aza.
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swe next examined if pre-incubation with 5-Aza would influence the
sensitivity of MIP101, RKO, HCT116 and HT29 CRC cells to 5-FU.
Results of clonogenic assays revealed fewer colonies in the MIP101
cells exposed to both 5-Aza and 5-FU, in comparison to exposure
to 5-FU alone (Figure 4D). These results correlate with the next set
of observations demonstrating a significant reduction in cell
viability in cells pre-incubated with 5-Aza before exposure to 5-FU
(Figure 4E). In MIP101 cells, pre-incubation with 5-Aza resulted in
a significant decrease in cell viability when cells were subsequently
treated with 1000mM of 5-FU in comparison to 5-FU alone: from
79.2±4.6% viable cells (5-FU only) to 45.1±1.3 (P¼0.000002). A
similar reduction was observed with RKO (from 58.4±8.1% viable
cells, 5-FU alone; to 19.4%±1.6, combination of 5-Aza and 5-FU,
P¼0.0008) and HT29 (from 71.1±2.0% viable cells, 5-FU; to
52.7±2.0%, combination 5-Aza and 5-FU, P¼0.00005) cells
(Figure 4E). HCT116 was the only cell line that did not respond
significantly to pre-incubation with 5-Aza.
To determine if the reduction in cell viability following
incubation with 5-Aza was occurring predominantly through its
effect on SPARC, we proceeded to knock-down SPARC expression
in our four CRC cell lines that were also exposed to 5-Aza and
later, 5-FU. Our results show that in the absence of SPARC, the
effect of 5-Aza in further reducing cell viability following exposure
to 5-FU could be abolished (Figure 4F). In MIP101 cells exposed to
5-Aza and 5-FU, cell viability increased from 45.2±1.3% (scramble
control) to 51.5±2.0% (SPARC siRNA) (P¼0.02). Similar results
were seen in RKO (increased from 19.4±1.6% to 39.0±1.6%,
P¼0.000006), and HT29 (increased from 52.7±1.9% to
69.8±2.8%, P¼0.0005). Only the response of HCT 116 cells to
SPARC siRNA remained unchanged. These observations indicate
that the ability of 5-Aza to improve sensitivity of cells to 5-FU
occurs, in part, by increasing SPARC gene expression following
demethylation of its promoter by 5-Aza.
The decrease in cell viability following incubation with 5-Aza
and 5-FU exposure can be attributed to an increase in apoptosis, as
significantly higher levels of caspase 3/7 were detected in MIP101,
RKO and HT29 cells exposed to the 5-Aza and 5-FU combination,
in comparison to 5-FU alone (Figure 5A). In MIP101 cells, caspase
3/7 levels increased from 17.7±1.3% (5-FU alone) to 25.4±2.8%
(5-Azaþ5-FU), P¼0.03; while in RKO and HT29 cells, levels
increased from 48.7±6.0% (5-FU alone) to 67.4±5.5% (5-Azaþ5-
FU), P¼0.04 and 38.5±1.5% (5-FU alone) to 44.3±3.3% (5-
Azaþ5-FU), P¼0.01 respectively. The effect of 5-Aza in
augmenting caspase 3/7 levels, and hence, apoptosis, was again
eliminated when SPARC gene expression was diminished following
transfection of cells with SPARC siRNA (Figure 5A). In fact,
reduction of SPARC by siRNA in all four cell lines dramatically
reduced the response to 5-FU, even in the presence of 5-Aza. These
observations were also confirmed by demonstrating significantly
greater numbers of TUNEL-positive cells in MIP101 cells
incubated with 5-Aza and 5-FU under similar conditions
(Figure 5B).
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sCell proliferation decreases in colorectal cancer cell lines
following incubation with 5-Aza-20deoxycytidine
We next examined the effect of exposing our various CRC cells to
5-Aza on cell proliferation, as we had previously shown that,
in vitro, higher levels of SPARC in cells were associated with
delayed cell cycle progression (Tai et al, 2005). The most dramatic
decrease in cell proliferation following incubation with 4mM 5-Aza
was again noted with MIP101 and RKO cells, which have complete
methylation of the SPARC promoter, beginning as early as 24h of
incubation (Figure 6A), with a 3- and 2.43-fold increase in
doubling time (from 0.8 days to 2.4 days, and 0.7 to 1.7 days) in
MIP101 and RKO, respectively (Figure 6B). In HCT 116 and HT29
cells with partial methylation of the SPARC promoter, a less
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observed when these cells were incubated with 5-Aza, which was
most noticeable after 2 days (Figure 6A and B).
Exposure to 5-FU, in addition to 5-Aza, resulted in a steady
decline in cell numbers in all cell lines, but most dramatically
within 24h, in both MIP101 and RKO cells in comparison to
HCT116 and HT 29 cells (Figure 6C and D).
DISCUSSION
We previously showed that SPARC gene and protein expression
was decreased in colorectal cancers and that lower levels were
associated with reduced sensitivity to chemotherapy (Tai et al,
2005). In this study, we proceeded to examine the methylation
status of the SPARC promoter, as aberrant methylation is
commonly observed in colorectal cancers (Toyota et al, 1999;
Lee et al, 2004), and recent studies in other cancers have revealed
aberrant hypermethylation of the SPARC promoter to be
responsible for low levels of SPARC expression (Sato et al, 2003;
Suzuki et al, 2005; DiMartino et al, 2006). We were able to identify
specific CpG sites that were consistently methylated in colorectal
cancers by DNA bisulfite sequencing. Moreover, we demonstrated
that repressed SPARC expression in colorectal cancer cell lines
resulting from aberrant hypermethylation, could be reversed
following exposure to a demethylating agent, 5-Aza-
20deoxycytidine, which resulted in increased SPARC expression
and enhanced sensitivity of colorectal cancer cells to 5-FU.
In colorectal cancer, the change in SPARC expression follows a
similar pattern as in pancreatic cancer: higher levels of SPARC are
observed in normal pancreatic ductal epithelial cells while it is
absent in the majority of pancreatic cancers (Sato et al, 2003). This
loss of SPARC gene expression was also associated with aberrant
hypermethylation which could be reversed by 5-Aza-
20deoxycytidine (Sato et al, 2003). Aberrant hypermethylation of
the SPARC promoter has also been observed in cancers of the lung
(Suzuki et al, 2005), prostate (Wang et al, 2005), endometrium
(Rodriguez-Jimenez et al, 2007) and leukaemia cell lines
(DiMartino et al, 2006). Recent studies using genome-wide
screening to identify genes that are targeted for aberrant
methylation in tumours have also consistently shown SPARC
expression to be inducible by 5-Aza-20deoxycytidine, in pancreatic
(Sato et al, 2003), cervical (Sova et al, 2006), and colorectal cancer
cell lines (Yang et al, 2007). In this study, we found an overall
methylation pattern of 60% in the SPARC promoter of primary
colorectal cancer specimens, while only 28% of the CpG sites were
partially methylated. Normal colon had an equal distribution of
complete, partial or no methylation of the SPARC promoter. This
variable distribution in methylation status in the normal colon is
interesting. The mean age of our subjects with normal colon was
54.2 years-old, while those with colorectal cancer was 66.4 years-
old, which may lead one to question if this observation may be due
to age-related methylation. However, differences in the methyla-
tion status of the SPARC promoter between a tumour specimen
(95% methylation) and its surrounding normal colonic epithelium
(50% methylation) were noted within the same individual, which
would argue against the possibility of an age-related phenomenon,
and instead, indicates that SPARC promoter hypermethylation in
tumours to be most likely related to a diseased state. It is possible
that the presence of complete or partial methylation in some
of these pathologically ‘normal’-appearing colonic epithelium may,
in fact, represent an early epigenetic event in the adenoma–
carcinoma sequence that will predispose these patients to
developing colorectal cancers. Our studies suggest that methyla-
tion of specific CpG sites (1–2, 8–10, 16–18) had the highest
frequency of hypermethylation in colorectal cancers, which may
prove useful as potential diagnostic or predictive markers of this
disease. This hypothesis will require a prospective study to
determine if partial or complete methylation of the SPARC
promoter in the ‘normal’ colon can be predictive of future
development of colonic polyps and later, colorectal cancers.
The results of our DNA bisulfite sequencing of the SPARC
promoter, spanning a region 1500bp upstream and including exon1/
intron1, allowed us to determine that the SPARC promoter
hypermethylation could be identified in 80% of cases of human
colorectal cancers (8 of 10 cancer). This finding differs from a recent
study by Yang et al (2007), where only partial methylation (and no
hypermethylation) was observed in their cases of colorectal cancers
within a shorter 221bp region of the SPARC promoter (Yang et al,
2007). One possible explanation to account for this difference
between our studies may be in the processing of the clinical samples:
all of the samples used in the current study were laser capture
microdissected to minimise potential contamination of either normal
colonic epithelium in our colorectal cancer specimens, and vice
versa. In the study by Yang and colleagues, bulk tissues were used.
Our results are also more in keeping with sequencing results of a
similar region spanning exon1/intron1 of SPARC in human
endometrial cancers, where 66% of the tumours were hypermethy-
lated (Rodriguez-Jimenez et al, 2007).
We recognise that 5-Aza-20deoxycytidine, a nucleoside anti-
metabolite and a potent inhibitor of DNA methyltransferase 1
(Dnmt1) activity, will have a global effect on other methylated
genes (Soengas et al, 2001; Zhu et al, 2001; Scott et al, 2006) and
does not specifically target SPARC. However, the results presented
in this study demonstrate that exposure of CRC cell lines to 5-Aza
effectively demethylated the CpG regions within the SPARC
promoter, leading to greater SPARC gene and protein expression.
We were also able to show that, in the absence of SPARC, the effect
of 5-Aza in enhancing chemotherapy sensitivity could be
abolished, thus indicating that, as a consequence of SPARC
promoter demethylation by 5-Aza, higher SPARC levels led to
greater chemosensitivity and improvements in chemotherapy
response. Moreover, our results demonstrate that 5-Aza was most
effective in those cell lines that either had complete hypermethyla-
tion of the SPARC promoter, such as MIP101 and RKO cells; or
cells with a hemimethylated status, such as HT 29 cells, that
responded to 5-Aza by completely demethylating the SPARC
promoter. These observations suggest that cells with the greatest
change in methylation status of the SPARC promoter in response
to 5-Aza pretreatment, became the most sensitive to chemotherapy
as a result of this increase in SPARC expression.
We previously showed that administration of exogenous SPARC,
in combination with chemotherapy, to be highly efficacious in
achieving tumour regression in animal xenografts (Tai et al, 2005),
and our current observations lead us to believe that the use of a
demethylating agent that restores SPARC expression can also be an
effective adjunct to chemotherapy in colorectal cancer, and
possibly other tumours with SPARC promoter hypermethylation.
The clinical utility of 5-Aza has been restricted to the treatment of
leukaemias and lymphomas (Karon et al, 1973; McCredie et al,
1973; Rivard et al, 1981), but no significant effect has been
demonstrated with solid tumours (Moertel et al, 1972) because of
two major reasons: (1) its short half life prevents adequate
accumulation deep within solid tumours, and (2) high doses
required to achieve clinical efficacy are associated with toxicity
(Abele et al, 1987). However, our results suggest that a
demethylating agent would function as a chemosensitiser and
therefore, lower doses could be administered in combination with
cytotoxic agents to achieve the desired clinical response.
To conclude, the findings of our current study demonstrate that:
(1) SPARC is frequently aberrantly methylated in colorectal
cancers, (2) specific methylated CpG sites have been identified
that are present within the SPARC promoter of colorectal cancers,
and (3) higher expression of SPARC can be achieved with 5-Aza-
20deoxycytidine, leading to improved sensitivity to chemotherapy.
Together, these results provide a promising rationale to explore
SPARC promoter methylation
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sand translate the findings into further potential clinical and
diagnostic therapeutic applications in colorectal cancer.
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